Loading...
Docoh

Pfizer (PFE)

Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives. It strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with its responsibility as one of the world's premier innovative biopharmaceutical companies, it collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, it has worked to make a difference for all who rely on it. It routinely posts information that may be important to investors on its website at www.Pfizer.com.

Company profile

Ticker
PFE
Exchange
Website
CEO
Albert Bourla
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Agouron Pharmaceuticals, LLC • AH Robins LLC • AHP Manufacturing B.V. • Alpharma Pharmaceuticals LLC • American Food Industries LLC • Amplyx Pharmaceuticals, Inc. • Anacor Pharmaceuticals, Inc. • Array BioPharma Inc. • Bamboo Therapeutics, Inc. • Blue Whale Re Ltd. ...

PFE stock data

Analyst ratings and price targets

Last 3 months

Calendar

10 Aug 22
12 Aug 22
31 Dec 22
Quarter (USD) Jul 22 Apr 22 Dec 21 Oct 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 1.82B 1.82B 1.82B 1.82B 1.82B 1.82B
Cash burn (monthly) 229.67M 49.5M (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) 302.47M 65.19M n/a n/a n/a n/a
Cash remaining 1.52B 1.76B n/a n/a n/a n/a
Runway (months of cash) 6.6 35.5 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
29 Jul 22 Rady A Johnson Phantom Stock Units SSP Common Stock Grant Acquire A No No 50.51 3 151.53 7,286
29 Jul 22 Jennifer B. Damico Phantom Stock Units SSP Common Stock Grant Acquire A No No 50.51 25 1.26K 18,322
29 Jul 22 Albert Bourla Phantom Stock Units SSP Common Stock Grant Acquire A No No 50.51 10 505.1 95,461
15 Jul 22 Rady A Johnson Phantom Stock Units SSP Common Stock Grant Acquire A No No 51.75 3 155.25 7,224
15 Jul 22 Jennifer B. Damico Phantom Stock Units SSP Common Stock Grant Acquire A No No 51.75 25 1.29K 18,150
66.2% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 3091 3173 -2.6%
Opened positions 144 563 -74.4%
Closed positions 226 135 +67.4%
Increased positions 1326 1215 +9.1%
Reduced positions 1301 1131 +15.0%
13F shares Current Prev Q Change
Total value 192.47B 221.77B -13.2%
Total shares 3.72B 3.76B -1.1%
Total puts 51.01M 75.09M -32.1%
Total calls 49.23M 73.29M -32.8%
Total put/call ratio 1.0 1.0 +1.1%
Largest owners Shares Value Change
Vanguard 479.07M $24.8B +3.0%
BLK Blackrock 408.08M $21.13B -0.5%
STT State Street 286.85M $14.85B +0.7%
Capital World Investors 219.88M $11.38B -7.2%
Wellington Management 216.67M $11.22B -2.1%
Geode Capital Management 104.9M $5.42B +3.8%
NTRS Northern Trust 66.51M $3.44B -2.2%
Charles Schwab Investment Management 59.83M $3.1B +13.2%
BAC Bank Of America 59M $3.05B +2.7%
BK Bank Of New York Mellon 54.63M $2.83B -0.1%
Largest transactions Shares Bought/sold Change
Norges Bank 0 -56.76M EXIT
Capital International Investors 38.53M +37.31M +3059.6%
BEN Franklin Resources 26.41M -17.78M -40.2%
Capital World Investors 219.88M -16.98M -7.2%
Vanguard 479.07M +13.79M +3.0%
Sanders Capital 0 -12.25M EXIT
Coatue Management 0 -10.31M EXIT
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 2.09M -10.16M -83.0%
Massachusetts Financial Services 43.39M +9.54M +28.2%
TROW T. Rowe Price 35.34M -7.92M -18.3%

Financial report summary

?
Risks
  • PRODUCT MANUFACTURING, SALES AND MARKETING RISKS
  • COLLABORATIONS AND OTHER RELATIONSHIPS WITH THIRD PARTIES
  • PRICING AND REIMBURSEMENT
  • U.S. HEALTHCARE REGULATION
  • DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS
  • POST-AUTHORIZATION/APPROVAL DATA
  • INTELLECTUAL PROPERTY PROTECTION
  • THIRD-PARTY INTELLECTUAL PROPERTY CLAIMS
  • INFORMATION TECHNOLOGY AND SECURITY
  • BUSINESS DEVELOPMENT ACTIVITIES
  • SPIN-OFF AND COMBINATION OF UPJOHN WITH MYLAN
  • CONSUMER HEALTHCARE JV WITH GSK
  • MARKET FLUCTUATIONS IN OUR EQUITY AND OTHER INVESTMENTS
  • COST AND EXPENSE CONTROL AND NONORDINARY EVENTS
  • INTANGIBLE ASSETS, GOODWILL AND EQUITY-METHOD INVESTMENTS
  • CHANGES IN LAWS AND ACCOUNTING STANDARDS

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
New words: admitted, bivalent, bleeding, broad, cardiomyopathy, cell, clarify, Clostridium, Codification, CureVac, DCM, decided, declaratory, dilated, disciplined, divert, Enanta, encoding, enterprise, evolve, exceed, exceeded, FASB, flexible, futility, GBT, gene, German, GmbH, Haleon, halted, heavy, HHS, Instagram, intensive, ix, Labour, lamin, LIBERTY, LMNA, London, lung, menstrual, monovalent, MSN, mutation, myeloma, NDA, nominally, peace, pharmacy, poor, pregnant, premenopausal, randomized, refractory, room, SE, sickle, similarly, simultaneously, situation, telehealth, Ukrainian, underserved, unvaccinated, urgent, vi, vii, viii, Welfare, withdrawal, women
Removed: Allogene, Aurobindo, breast, CentreOne, equal, greater, initiate, PTAB, recoverability, rolling, Teva, undertaken, USA

Patents

Utility
Sulfonyl Amide Derivatives for the Treatment of Abnormal Cell Growth
11 Aug 22
Inventors: Michael Joseph Luzzio, Kevin Daniel Freeman-Cook, Samit Kumar Bhattacharya, Matthew Merrill Hayward, Catherine Angela Hulford, Christopher Lowell Autry, Xumiao Zhao, Jun Xiao, Kendra Louise Nelson
Utility
Protein Tyrosine Phosphatase Inhibitors
11 Aug 22
Inventors: James Francis BLAKE, Mark Laurence BOYS, Mark Joseph CHICARELLI, Adam Wade COOK, Mohamed S. A. ELSAYED, Jay Bradford FELL, John P. FISCHER, Ronald Jay HINKLIN, Yutong JIANG, Oren Teague MCNULTY, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Christina Elizabeth WONG
Utility
Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives
11 Aug 22
Inventors: Oleg Brodsky, Samantha Elizabeth Greasley, Robert Louis Hoffman, Pei-Pei Kung, Paul Francis Richardson, Paul Anthony Stupple
Utility
PD-1 Axis Binding Antagonist to Treat Cancer with Genetic Mutations In Specific Genes
4 Aug 22
The present disclosure describes combination therapies comprising a PD-1 axis binding antagonist, wherein the cancer has been pre-determined to have one or more genetic mutations in one or more genes, to have certain gene expression profiles, and/or to have other biomarkers.
Utility
Combination Therapies Using CDK Inhibitors
4 Aug 22
This invention relates to a method for treating cancer by administering a CDK4/6 or a CDK2/4/6 inhibitor in combination with a PD-1 axis binding antagonist, and optionally an OX40 agonist and/or a 4-1BB agonist to a subject in need thereof.